BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

July 29, 2026 | News

Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

July 29, 2026 | News

AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development

AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...

July 29, 2026 | News

Asymchem Achieves First USFDA Inspection Milestone for Carbapenem API Manufacturing Facility

Asymchem, a leading global contract development and manufacturing organization (CDMO), announced that its dedicated carbapenem API manufacturing facil...

July 28, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...

July 27, 2026 | Company results

Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...

July 24, 2026 | News

Discount or Validation? Western Pharma’s Appetite for Chinese Assets

There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...

July 24, 2026 | Analysis

Alebund Doses First Participant in Global Phase IIb Trial of AP306 for Hyperphosphatemia

Alebund Pharmaceuticals a renal-focused biopharmaceutical company, announced that the first participant has been randomized and dosed in the global Phase I...

July 23, 2026 | News

China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer

SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...

July 21, 2026 | News

Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...

July 17, 2026 | News

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 16, 2026 | News

Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...

July 16, 2026 | News

Stay Connected